{"id":9639,"date":"2026-10-29T16:52:41","date_gmt":"2026-10-29T11:22:41","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/syngene-share-price-today-2026-10-29\/"},"modified":"2026-10-29T16:52:43","modified_gmt":"2026-10-29T11:22:43","slug":"syngene-share-price-today-2026-10-29","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/syngene-share-price-today-2026-10-29\/","title":{"rendered":"Syngene International Share Price Today: Rises 10.77% in 3 Trading Sessions | 29 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: SYNGENE<\/strong> \u00b7 29 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b9398.60<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-2.98%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b9414.00 \/ \u20b9396.20<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b9410.85<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>33.32 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>29 October 2026 \u00b7 03:25 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Syngene International has risen 10.77% over 3 trading sessions; today&#x27;s move is -2.98%.<\/li>\n<li>Syngene reported a sequential revenue increase of 13% for Q2 FY27 to \u20b9833 crore, with an operating EBITDA margin of 18% and profit after tax before exceptional items at \u20b938 crore. The company secured its first manufacturing agreement for the Bayview biologics facility in the U.S. and expanded its integrated drug discovery leadership under Dr. Jayashree Aiyar. However, on a year-on-year basis, revenue declined 9% due to lower Zoetis revenues and forex hedge losses.<\/li>\n<li>Trading volume was 1.39 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Syngene International share price: 10.77% rise over 3 trading sessions<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Syngene International Ltd. (SYNGENE) declined 2.98% today, settling at \u20b9398.60 after moving within a intraday range of \u20b9396.20 to \u20b9414.00.<\/p>\n<p class=\"wt-copy\">The broader market and sector showed positive momentum, with the Nifty benchmark gaining 1.05% and the Nifty Pharma sector index advancing 0.64%. Syngene&#x27;s pullback ran counter to the positive close of its sectoral index, pointing to stock-specific price adjustments following its recent strong run.<\/p>\n<p class=\"wt-copy\">The move follows the company&#x27;s recent Q2 FY27 financial disclosures released on October 27, 2026, which reported sequential revenue growth of 13% to \u20b9833 crore and an operating EBITDA margin of 18%, alongside several leadership and management changes. While these operational updates provide medium-term context, the day&#x27;s downward movement appears consistent with profit-taking after the stock&#x27;s prior sessions posted multi-percentage gains.<\/p>\n<p class=\"wt-copy\">33.32 lakh shares traded by 29 October 2026 \u00b7 03:25 PM IST. This compares with a 20-day average daily volume of 23.93 lakh shares (1.39 times). The five-day average daily volume was 71.57 lakh shares. Separately, the NSE report for 28 October 2026 showed 45.87 lakh shares delivered, representing 13.91% of that day\u2019s traded volume. The same report recorded 447,917 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Profit-taking after recent gains amid broader sector divergence<\/strong><\/p>\n<p class=\"wt-copy\">The stock retreated by 2.98% despite a positive close in the Nifty Pharma sector, following strong prior session returns of 12.19% and 14.17% over the last two and three trading days. Cash volume reached 1.39 times the 20-day average, supported by a delivery quantity of 4,586,751 shares representing 13.91% of total traded volume on October 28, 2026, pointing to normal profit-taking and technical retracement.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Q2 FY27 Financial Results and Operating Performance<\/div>\n<div class=\"wt-card-date\">28 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Syngene reported a sequential revenue increase of 13% for Q2 FY27 to \u20b9833 crore, with an operating EBITDA margin of 18% and profit after tax before exceptional items at \u20b938 crore. The company secured its first manufacturing agreement for the Bayview biologics facility in the U.S. and expanded its integrated drug discovery leadership under Dr. Jayashree Aiyar. However, on a year-on-year basis, revenue declined 9% due to lower Zoetis revenues and forex hedge losses.<\/p>\n<p class=\"wt-copy\">Quarterly earnings results and new contract wins provide essential fundamental baselines for evaluating the company&#x27;s CDMO growth trajectory and margin recovery.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Senior Management and Leadership Transitions<\/div>\n<div class=\"wt-card-date\">28 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company announced multiple executive changes, including the resignation of Ajay Tandon as Head of Strategy and Corporate Development effective October 30, 2026, and the departure of Chief Financial Officer Deepak Jain, who will step down after a transition period. Additionally, chemistry and biology heads Subhendu Kumar and Priyaranjan Pattanaik transitioned from senior management personnel to non-SMP categories.<\/p>\n<p class=\"wt-copy\">Executive departures and role restructuring highlight ongoing organizational realignment within key corporate and scientific leadership positions.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">28 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 27, 2026, titled &quot;Syngene reports sequential revenue growth of 13% in Q2 FY27; Operating EBITDA margin improves by 6 percentage points&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/SYNGENE2_27102026203515_PRQ2FY2027_Signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Outcome of Board Meeting<\/div>\n<div class=\"wt-card-date\">28 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Syngene International Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/SYNGENE2_27102026193349_OutcomeQ2FY27_Signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">28 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 27, 2026, titled &quot;Syngene reports sequential revenue growth of 13% in Q2 FY27; Operating EBITDA margin improves by 6 percentage points&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/SYNGENE2_27102026203515_PRQ2FY2027_Signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">52.59%<\/div>\n<div class=\"wt-note\">52.59% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">10.14%<\/div>\n<div class=\"wt-note\">11.82% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">39.44%<\/div>\n<div class=\"wt-note\">39.84% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1739456_15102026103042_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>ANJAN CHAKRABARTI<\/strong><span class=\"wt-note\">Employees\/Designated Employees<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Sell<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>6,190 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>27 December 2024<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>ANJAN CHAKRABARTI<\/strong><span class=\"wt-note\">Employees\/Designated Employees<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Sell<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>27,200 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>20 December 2024<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>ANJAN CHAKRABARTI<\/strong><span class=\"wt-note\">Employees\/Designated Employees<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>58,390 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>19 December 2024<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Biocon Limited<\/strong><span class=\"wt-note\">Promoters<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Sell<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>80.00 lakh shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>10 December 2024<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>DEEPAK VENKATRAMAN<\/strong><span class=\"wt-note\">Employees\/Designated Employees<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Sell<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>600 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>25 November 2024<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 27.10% on 30 September 2026. This compares with 25.78% on 30 June 2026, a change of +1.32 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 28 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">NIPPON LIFE INDIA TRUSTEE LTD-A\/C NIPPON INDIA PHA<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">3.23 crore shares \u00b7 8.00%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">ICICI PRUDENTIAL MNC FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.75 crore shares \u00b7 6.82%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">DSP NIFTY 500 INDEX FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.90 crore shares \u00b7 4.71%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1739456_15102026103042_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution progress on the newly signed Bayview biologics facility manufacturing agreement with a large pharmaceutical customer<\/li>\n<li>Transition timeline and appointment process for the incoming Chief Financial Officer<\/li>\n<li>Realization of benefits from completed manpower-related cost-optimization initiatives over upcoming quarters<\/li>\n<li>Volume trends and cash delivery participation relative to the 20-day average volume<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/syngene-share-price-today-2026-10-28\/\">Syngene International Share Price Today: Rises 12.55% in 2 Trading Sessions | 28 October 2026 \u2014 28 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/syngene-share-price-today-2026-10-27\/\">Syngene International Share Price Today: Why SYNGENE Is Rising 1.76% | 27 October 2026 \u2014 27 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/syngene\/\">More Syngene International news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Syngene International company news?<\/h3>\n<p class=\"wt-copy\">Syngene reported a sequential revenue increase of 13% for Q2 FY27 to \u20b9833 crore, with an operating EBITDA margin of 18% and profit after tax before exceptional items at \u20b938 crore. The company secured its first manufacturing agreement for the Bayview biologics facility in the U.S. and expanded its integrated drug discovery leadership under Dr. Jayashree Aiyar. However, on a year-on-year basis, revenue declined 9% due to lower Zoetis revenues and forex hedge losses.<\/p>\n<h3>How strong was Syngene International\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">33.32 lakh shares traded, 1.39 times the 20-day average daily volume. The price and volume data are dated 29 October 2026 \u00b7 03:25 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/syngene-share-price-today-2026-10-29\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/syngene-share-price-today-2026-10-29\/\"}, \"headline\": \"Syngene International Share Price Today: Rises 10.77% in 3 Trading Sessions | 29 October 2026\", \"description\": \"Syngene International has risen 10.77% over 3 trading sessions. Today it is 2.98% lower at \u20b9398.60. See price context, volume and key company developments.\", \"datePublished\": \"2026-10-29T16:52:30.963892+05:30\", \"dateModified\": \"2026-10-29T16:52:30.963892+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Syngene International\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"SYNGENE\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/syngene-company-news-2026-10-29.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Resignation of Director\/KMP\/SMP\",\"summary\":\"Resignation of Director\/KMP\/SMP\",\"source\":\"NSE\",\"published\":\"27-Oct-2026 21:23:47\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SYNGENE_ROID_102006_KMP_Doc.zip\"},{\"title\":\"Press Release\",\"summary\":\"a press release dated October 27, 2026, titled \\\"Syngene reports sequential revenue growth of 13% in Q2 FY27; Operating EBITDA margin improves by 6 percentage points\\\".\",\"source\":\"NSE\",\"published\":\"27-Oct-2026 20:38:00\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SYNGENE2_27102026203515_PRQ2FY2027_Signed.pdf\"},{\"title\":\"Change in Management\",\"summary\":\"change in Management\",\"source\":\"NSE\",\"published\":\"27-Oct-2026 20:17:31\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SYNGENE2_27102026201706_SEDisclosureSMPKMP_Signed.pdf\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Syngene International Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"source\":\"NSE\",\"published\":\"27-Oct-2026 19:35:23\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SYNGENE2_27102026193349_OutcomeQ2FY27_Signed.pdf\"}],\"recent_news\":[{\"summary\":\"a press release dated October 27, 2026, titled \\\"Syngene reports sequential revenue growth of 13% in Q2 FY27; Operating EBITDA margin improves by 6 percentage points\\\".\",\"category\":\"Press Release\",\"date\":\"27-Oct-2026 20:38:00\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SYNGENE2_27102026203515_PRQ2FY2027_Signed.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Syngene International Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"27-Oct-2026 19:35:23\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SYNGENE2_27102026193349_OutcomeQ2FY27_Signed.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Resignation of Mr. Pramuch Goel as Head Corporate Affairs & Communications and a member of Executive Committee (Senior Management Personnel) of the company effective. close of business hours of September 21, 2026.\",\"category\":\"Resignation\",\"date\":\"21-Sep-2026 22:50:57\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SYNGENE2_21092026224924_SEDisclosure_Sept212026.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":5},{\"summary\":\"the Communication regarding remittance of final dividend for the FY 2025-26.\",\"category\":\"General Updates\",\"date\":\"10-Sep-2026 17:18:35\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SYNGENE2_10092026171321_SEIntimationDividendletter_Signed.pdf\",\"headline\":\"Shareholder-return \/ corporate action\",\"impact\":\"This affects shareholder returns or the share structure and can influence near-term investor interest.\",\"importance_score\":3,\"completeness_score\":3}],\"insider_activity\":[{\"person\":\"ANJAN CHAKRABARTI\",\"category\":\"Employees\/Designated Employees\",\"type\":\"Sell\",\"quantity\":\"6190\",\"post_holding\":\"25000\",\"date\":\"27-Dec-2024\",\"mode\":\"Market Sale\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"ANJAN CHAKRABARTI\",\"category\":\"Employees\/Designated Employees\",\"type\":\"Sell\",\"quantity\":\"27200\",\"post_holding\":\"31190\",\"date\":\"20-Dec-2024\",\"mode\":\"Market Sale\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"ANJAN CHAKRABARTI\",\"category\":\"Employees\/Designated Employees\",\"type\":\"Buy\",\"quantity\":\"58390\",\"post_holding\":\"58390\",\"date\":\"19-Dec-2024\",\"mode\":\"ESOP\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"Biocon Limited\",\"category\":\"Promoters\",\"type\":\"Sell\",\"quantity\":\"8000000\",\"post_holding\":\"211185608\",\"date\":\"10-Dec-2024\",\"mode\":\"Market Sale\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"DEEPAK VENKATRAMAN\",\"category\":\"Employees\/Designated Employees\",\"type\":\"Sell\",\"quantity\":\"600\",\"post_holding\":\"2120\",\"date\":\"25-Nov-2024\",\"mode\":\"Market Sale\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"DEEPAK VENKATRAMAN\",\"category\":\"Employees\/Designated Employees\",\"type\":\"Sell\",\"quantity\":\"600\",\"post_holding\":\"1520\",\"date\":\"26-Nov-2024\",\"mode\":\"Market Sale\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"Mayank Verma\",\"category\":\"Employees\/Designated Employees\",\"type\":\"Sell\",\"quantity\":\"1500\",\"post_holding\":\"1250\",\"date\":\"26-Nov-2024\",\"mode\":\"Market Sale\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"ALOK MEHROTRA\",\"category\":\"Employees\/Designated Employees\",\"type\":\"Buy\",\"quantity\":\"20000\",\"post_holding\":\"55266\",\"date\":\"14-Nov-2024\",\"mode\":\"ESOP\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"ALOK MEHROTRA\",\"category\":\"Employees\/Designated Employees\",\"type\":\"Sell\",\"quantity\":\"8200\",\"post_holding\":\"47066\",\"date\":\"14-Nov-2024\",\"mode\":\"Market Sale\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"SIBAJI BISWAS\",\"category\":\"Key Managerial Personnel\",\"type\":\"Buy\",\"quantity\":\"86431\",\"post_holding\":\"154470\",\"date\":\"07-Nov-2024\",\"mode\":\"ESOP\",\"source\":\"NSE PIT disclosure\"}],\"promoter_pledge\":{\"summary\":\"An NSE promoter pledge\/encumbrance filing was identified, but the available filing text could not be reduced reliably to a concise current pledge figure.\",\"events\":[{\"summary\":\"Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com DECLARATION Under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 To, The Chairperson Audit Committee Syngene International Limited To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai \u2013 400 001 To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai \u2013 400 051 Dear Sir\/Madam, In pursuance of Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we hereby declare that none of the entities belonging to the Promoter and Promoter Group Category along with the Persons acting in concert (PAC) have made any encumbrance on the shares directly or indirectly held by them in the Company, at any time during or as on the last date of the financial year 2025-26 i.e. March 31, 2026. Kindly take the above on record. Thanking you, For Biocon Limited _\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"23-Apr-2026 14:29:07\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_sandeshc_13042026123500_46.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":52.59,\"public_pct\":47.0,\"fii_pct\":10.14,\"dii_pct\":29.3,\"mf_pct\":27.1,\"institutional_pct\":39.44,\"noninst_pct\":7.56,\"mf_scheme_count\":28,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"NIPPON LIFE INDIA TRUSTEE LTD-A\/C NIPPON INDIA PHA\",\"shares\":32295397,\"pct\":8.0},{\"name\":\"ICICI PRUDENTIAL MNC FUND\",\"shares\":27528631,\"pct\":6.82},{\"name\":\"DSP NIFTY 500 INDEX FUND\",\"shares\":19018962,\"pct\":4.71},{\"name\":\"SBI NIFTY SMALLCAP 250 ETF\",\"shares\":12528672,\"pct\":3.1},{\"name\":\"MIRAE ASSET FOCUSED FUND\",\"shares\":4258501,\"pct\":1.05}],\"period\":\"30-SEP-2026\",\"submission_date\":\"15-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1739456_15102026103042_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":52.59,\"previous_fii_pct\":11.82,\"previous_dii_pct\":28.02,\"previous_mf_pct\":25.78,\"previous_institutional_pct\":39.84,\"previous_mf_scheme_count\":26,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null}} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Syngene International has risen 10.77% over 3 trading sessions. Today it is 2.98% lower at \u20b9398.60. See price context, volume and key company developments.<\/p>\n","protected":false},"author":1,"featured_media":9638,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Syngene International Share Price Today: Rises 10.77% in 3 Trading Sessions | 29 October 2026","_witty_meta_description":"Syngene International has risen 10.77% over 3 trading sessions. Today it is 2.98% lower at \u20b9398.60. See price context, volume and key company developments.","_witty_primary_phrase":"Syngene International share price today","_witty_reason_label":"Profit-taking after recent gains amid broader sector divergence","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[311],"class_list":["post-9639","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-syngene"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=9639"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9639\/revisions"}],"predecessor-version":[{"id":9640,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9639\/revisions\/9640"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/9638"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=9639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=9639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=9639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}